• Profile
Close

Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under Peritoneal Dialysis First policy

BMC Nephrology Feb 10, 2020

Wong CKH, Chen J, Fung SKS, et al. - Researchers focused on the lifetime cost-effectiveness of first-line dialysis modalities for end-stage renal disease (ESRD) patients under the “Peritoneal Dialysis First” policy. From both healthcare provider and societal perspectives, they conducted lifetime cost-effectiveness analyses using Markov modelling by simulating at age 60. They noted that the peritoneal dialysis (PD) group [USD$76,915; 7.13 quality-adjusted life-years (QALYs)] dominated hospital-based haemodialysis (HD) group (lifetime cost USD$142,389; 6.58 QALYs), for lifetime cost-effectiveness analysis from the perspective of healthcare provider. Findings revealed PD as a cost-saving first-line dialysis modality, compared with hospital-based HD, from both healthcare provider and societal perspectives, and thus, the existing PD First or favoured policy was supported in this study. As first-line dialysis modality for ESRD patients, Nocturnal home Home-based HD vs PD was considered cost-effective.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay